Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: personalised medicine + therapy control + antibody  Related to the article below (Last Update: 5/12/2008)

Specific melanoma proteins identified
ecancermedicalscience, UK - May 9, 2008
The patients could then receive drugs that target these proteins to more effectively treat their disease; potentially personalised cancer treatment that ...

Times Online
British scientists at front of ?500m worldwide project to
Times Online, UK - Apr 29, 2008
Insights from the ambitious initiative, which hopes to complete its task within ten years, will open a new era in personalised cancer medicine, ...
E-health: System to predict glucose levels
Irish Medical Times, Ireland - Apr 22, 2008
... the most eminent experts in medicine, science and technology to create a unique system to improve diabetes control, optimise therapy and ensure better ...

Printed Electronics World (press release)
7.1 M Euro grant to fund development of portable DIAdvisor?
Printed Electronics World (press release), UK - Apr 14, 2008
... fields of medicine, healthcare, science and technology to enable the creation of a totally unique system to improve diabetes control, optimise therapy, ...
Quest to unlock cancer genes
Irish Independent, Ireland - Apr 29, 2008
Insights from the ambitious initiative, which is hoped to be completed within 10 years, will open a new era in personalised cancer medicine, ...
Molecular change may reveal risk of leukaemia relapse
Science Centric, Bulgaria - May 1, 2008
'This could truly help advance personalised health care.' Grants from the National Cancer Institute and the Coleman Leukaemia Research Foundation supported ...

In order to show you the most relevant results, we have omitted some entries very similar to the 6 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by … -
DI Gabrilovich, T Ishida, S Nadaf, JE Ohm, DP … - Clinical Cancer Research, 1999 - AACR
... 2008: Cancer Clinical Trials and Personalized Medicine AACR Night ... University School
of Medicine, Nashville, Tennessee ... Therapy with anti-mouse VEGF antibody (10 ...

… CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody … -
R Stein, Z Qu, S Chen, A Rosario, V Shi, M Hayes, … - Clinical Cancer Research, 2004 - AACR
... 2008: Cancer Clinical Trials and Personalized Medicine Cancer and ... Center, Center
for Molecular Medicine and Immunology ... In vivo therapy studies were performed in ...

Combined vascular targeted imaging and therapy: A paradigm for personalized treatment -
KCP Li, S Guccione, MD Bednarski - Journal of Cellular Biochemistry, 2002 - doi.wiley.com
... angiogenesis: Biologic implications for antiangiogenic therapy. ... A possible control
point in ... Personalized medicine: Revolutionizing drug discovery and patient ...

… Colony-stimulating Factor (GM-CSF) Products in Patients Undergoing Combination Therapy with GM-CSF -
M Wadhwa, ALH Skog, C Bird, P Ragnhammar, M … - Clinical Cancer Research, 1999 - AACR
... Cancer Clinical Trials and Personalized Medicine Cancer Biostatistics ... Patients
Undergoing Combination Therapy with GM ... Standards and Control, Hertfordshire EN6 ...

Connective Tissue Growth Factor-Specific Monoclonal Antibody Therapy Inhibits Pancreatic Tumor … -
N Dornhofer, S Spong, K Bennewith, A Salim, S … - Cancer Research, 2006 - AACR
... Medicine 2008: Cancer Clinical Trials and Personalized Medicine ... Stanford University
School of Medicine, Room 1255 ... the potential of targeting CTGF for therapy. ...

A functional variant in FcRH3, encoding Fc Receptor Homolog 3, is associated with rheumatoid … -
Y Kochi, R Yamada, A Suzuki, JB Harley, S … - Nature genetics, 2005 - pubmedcentral.nih.gov
... 13 Research Group for Personalized Medicine, SNP Research Center, RIKEN ... in a second
Japanese case-control set ... clinical trial of B-cell-depleting therapy 44 , the ...

Molecular imaging and therapy directed at the neovasculature in pathologies -
S Guccione - Engineering in Medicine and Biology Magazine, IEEE, 2004 - ieeexplore.ieee.org
... Prior to the design of personalized treatment, molecular ... of molecular imaging on
clinical and preclinical medicine. ... used for imaging and therapy was presented. ...

Pharmacogenetics/genomics and personalized medicine -
W Sadee, Z Dai - Human Molecular Genetics, 2005 - Oxford Univ Press
... advances in drug therapy require an ... using medical informatics for optimizing
personalized medicine. ... Moving towards individualized medicine with pharmacogenomics ...

Role of pharmacoproteomics in the development of personalized medicine -
KK Jain - pgs, 2004 - Future Medicine
... a result of these develop- ments, pharmacological therapy is likely ... will facilitate
the practice of personal- ized medicine. ... 2. Jain KK: Personalised medicine. ...

Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy -
R Danesi, M Mosca, U Boggi, F Mosca, M Del Tacca - Molecular Medicine Today, 2000 - Elsevier
... increasing number of patients with high medical risk profile ... 7. The future of
immunosuppressive therapy. ... in the future should include personalized profiling by ...

Source: Google Scholar

Personalised Medicine: Therapy Control Of Humanised Antibodies
CENiMED GmbH, BioTeZ Berlin-Buch GmbH and Invitek Gesellschaft für Biotechnik & Biodesign mbH (company for biotechnology and bio-design) announce their cooperation in the development, production and marketing of Recovery-ELISAs for therapy control of a new group of therapeutics, the so called humanised antibodies.

Humanised antibodies offer unforeseen potentialities in cancer therapy, e. g. for the treatment of mamma carcinoma. Previous therapy control methods, however, could not avoid overdoses which had caused adverse reactions with the patients. Recovery-ELISA (R-ELISA) is an innovative, patented ELISA technique for the determination of the exact efficacy concentration of the therapeutic antibodies and the therapy control.
The automation of this technique will be established by a renowned platform manufacturer and then will be made available for the patients and the pharmaceutical industry.

"For the first time possibilities for a patient-specific therapy with humanised antibodies will be available" expresses Dr. Bendzko, CEO of Invtek Gesellschaft für Biotechnik & Biodesign mbH.

Dr. Pavel Strohner, CEO of BioTeZ Berlin-Buch GmbH and developer of this novel R-ELISA test, is a leading expert in the field of ELISA technology. The Berlin location is proud of this epochal development. This is yet another demonstration of the potentials and successes of a cooperation of several innovative biotechnological companies.

"This is yet another important milestone for the implementation of personalised medicine with the patients" complements Dr. Volker Muschalek, CEO of CENiMED GmbH.

About CENiMED GmbH

CENiMED GmbH - Centre for Individualised Medicine - was established in 2003 as a spin-off of the Charité Universitätsmedizin Berlin, Germany, with the intention to commercialise the results of medical fundamental research in the field of pharmacogenomics. It is a leading bio-medical company in the area of pharmacogenomic services. The company focuses on the development and marketing of services and products for the pharmaceutical industry. Herewith, CENiMED supports their clients from the early phases of drug development to post marketing studies. CENiMED is located in the Biotech Park, Berlin-Buch, Germany and possesses state-of-the-art genotyping and gene expression laboratories. Its mission is the development of early diagnostic and prognostic products on the basis of patent specific biomarkers.

About BioTeZ GmbH

Biotez Berlin-Buch GmbH, is a biotechnologically oriented company, was established 10 years ago and is situated on the Biotech campus Berlin-Buch since 1992

BioTeZ focuses on the following areas: Bio-diagnostics and food analytics, scientific services for genetic research and biotechnology and Custom oligonucleotide synthesis.

Additionally, the companies' experts have special experience and know-how in the conjugation and labelling of bio molecules (with HRP, FITC a. o.), development of monoclonal and polyclonal antibodies, ELISA development, Streptavidin coating (high biotin binding capacity, high chemo- and thermo stability) and immuno-affinity columns and chromatography.

About Invitek Gesellschaft für Biotechnik & Biodesign mbH

Invitek GmbH is a world-wide operating company that offers innovative products and technical support for the Life Science and diagnostics industries.

Founded in 1992, the company is known internationally for its outstanding and powerful technology platforms and also offers a wide range of innovative products for the nucleic acid purification, molecular diagnostics, the pharmaceutical industry and bio medical research. Within the modular product concept "I-tek solution", Invitek combines its technological developments in complete solutions for molecular diagnostics. An example is the successful introduction of an early warning system for colon carcinoma.

The company is certified according to DIN EN ISO 9001:2000 and EN ISO 13485:2003 and manufactures according to EC Directive 98/79/EEC (IVD-MD).

http://www.invitek.de
http://www.biotez.de
http://www.cenimed.com
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.